Press Releases from Chemotherapy-Induced Nausea And Vomiting Drugs (1 total)
Global Chemotherapy-Induced Nausea And Vomiting Drugs Market to grow at a CAGR o …
About CINV Drugs
The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.
Technavios analysts forecast the…
